IKBKB and rheumatoid arthritis: A large number of compounds were patented in 2005 by Pharmacia Corporation [23] as potential drugs for inflammatory diseases, in particular as inhibitors of IKK-2, an IkB kinase involved in the inflammatory response that is the main cause of rheumatoid arthritis (RA) onset.